Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C. Weltens
Prevalent Breast Cancer Patients With a Homozygous Mutant Status for CYP2D6*4: Response and Biomarkers in Tamoxifen Users
Breast Cancer Research and Treatment
Cancer Research
Oncology
Related publications
Comprehensive CYP2D6 Genotype and Adherence Affect Outcome in Breast Cancer Patients Treated With Tamoxifen Monotherapy
Breast Cancer Research and Treatment
Cancer Research
Oncology
Pharmacogenetics and Breast Cancer Endocrine Therapy: CYP2D6 as a Predictive Factor for Tamoxifen Metabolism and Drug Response?
Expert Reviews in Molecular Medicine
Molecular Medicine
Molecular Biology
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated With Tamoxifen
Frontiers in Pharmacology
Pharmacology
CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply
British Journal of Clinical Pharmacology
Pharmacology
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
Journal of Clinical Pharmacology
Pharmacology
Tamoxifen and Mastectomy for Elderly Patients With Operable Breast Cancer.
BMJ
Investigational Drug Combined With Chemotherapy Improves Response in Patients With BRCA -Mutant Breast Cancer
Cancer
Cancer Research
Oncology
The Relationship Between the CYP2D6 Polymorphisms and Tamoxifen Efficacy in Adjuvant Endocrine Therapy of Breast Cancer Patients in Chinese Han Population
International Journal of Cancer
Cancer Research
Oncology
C–X–C Ligand 10 and C–X–C Receptor 3 Status Can Predict Tamoxifen Treatment Response in Breast Cancer Patients
Breast Cancer Research and Treatment
Cancer Research
Oncology
